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Abstract
Background: Mutations in a small region of the rpoB gene are responsible for most rifamycin
resistance in Mycobacterium tuberculosis. In this study we have sequentially generated resistant
strains to first rifampicin and then rifabutin. Portions of the rpoB gene were sequenced from 131
randomly selected mutants. Second round selection resulted in a changed frequency of specific
mutations.
Methods: Mycobacterium tuberculosis (strain Mtb72) rifamycin resistant mutants were selected in
vitro with either rifampicin or rifabutin. One mutant R190 (rpoB S522L) selected with rifampicin had
a rifampicin MIC of 32 µg/ml but remained sensitive to rifabutin (MIC<0.8 µg/ml). This mutant was
subjected to a second round of selection with rifabutin.
Results: All 105 first round resistant mutants derived from the parent strain (Mtb72) screened
acquired mutations within the 81 bp rpoB hotspot. When the rifampicin resistant but rifabutin
sensitive S522L mutant was subjected to a second round of selection, single additional rpoB
mutations were identified in 24 (92%) of 26 second round mutants studied, but 14 (54%) of these
strains contained mutations outside the 81 bp hotspot (codons 144, 146, 148, 505). Additionally,
spontaneous rifabutin resistant mutants were produced at >10 times the frequency by the S522L
mutant than the parent strain.
Conclusion: First round selection of mutation S522L with rifampicin increased the frequency and
changed the spectrum of mutations identified after selection with rifabutin.
Introduction
It has been estimated that one third of the World's popu-
lation is infected with Mycobacterium tuberculosis (MTB)
resulting in 2 million deaths annually. In uncomplicated
cases short course therapy (6 months) using a multiple-
drug regimen is highly effective. An essential component
of this regimen is rifampicin (RIF). In MTB resistance to
antimicrobial agents appears to be solely due to
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genetic elements carrying a resistance genotype has been
described. For this reason MTB strains or sub-populations
with an unusual spectrum or rate of mutations are of con-
siderable interest [1-3] as potentially they are more prone
to develop resistance to antimicrobial drugs.
Mutations within an 81-bp locus of MTB rpoB have been
seen in almost all (> = 95%) rifamycin resistant isolates,
whether they be clinical [4] or laboratory generated
mutants [5]. These mutations are not only markers of
resistance as the region of RpoB coded for by this locus
has been shown to bind rifamycins and mutations in this
region allow RpoB to function in the presence of rifamy-
cins [6]. Although mutations associated with RIF resist-
ance have been reported throughout this locus, mutations
in two codons account for approximately 70% of all
mutants identified (codon-526 approximately 20%, and
codon-531 approximately 50%), from most collections of
isolates studied.
Rifabutin (RFB) is a second therapeutically useful rifamy-
cin, which is often used when M. avium / intracellulare
(MAI) infection is suspected or confirmed. RIF and RFB
resistances are not invariably cross-resistant although the
most common mutations (codons 526 and 531) are
reported to result in high-level resistance to both drugs.
Certain mutations in other codons, notably 511, 516, and
specific mutations in 522, however, have been reported to
result in lower level resistance to RIF only [7,8].
Here we report the generation and characterisation
(sequencing subgenic fragments of the rpoB gene) of two
sets of rifamycin resistant mutants selected from a single
parent strain using either RIF or RFB. Mutations that con-
fer resistance to RIF but not RFB cannot be selected for by
RFB. Thus certain mutations are not possible when RFB is
used for the selection of mutant cells and different selec-
tions and/or frequencies of mutations would be expected.
Strains with mutations conferring resistance to RIF only
can be subjected to a second round of selection with RFB
and the type and frequency of resistant mutants compared
to that of the sensitive parent strain [2]. In this study the
single isolate identified with resistance to RIF only, was
subjected to a second round of selection with RFB; after
which rpoB gene fragments of 26 randomly selected colo-




Mycobacterium tuberculosis Mtb72 (ATCC35801) belongs
to the Haarlem genotype and was the parent strain of all
isolates generated in this study.
Generation and selection of mutants
Bacteria were cultured in Middlebrook 7H9 (Difco) broth
for 14 days in a shaking incubator at 37°C. Then 0.5 ml
of broth was plated out onto Middlebrook 7H11 (Difco)
media containing either RIF 8 µg/ml (Sigma) or RFB 0.8
µg/ml (Pharmacia Corporation, MI, USA) for the first
round selection or 0.8 µg/ml and 8 µg/ml RFB for the sec-
ond round selection. These plates were incubated at 37°C
and colonies picked between 21 and 42 days culture.
Selected colonies were streaked on drug containing media
to confirm the resistant phenotype (RFB 0.8 µg/ml, RIF 8
µg/ml).
MICs were measured on Middlebrook 7H11 plates con-
taining serial dilutions RIF (512 µg/ml to 4 µg/ml) or RFB
(128 µg/ml to 1 µg/ml) for 24 isolates chosen so as to rep-
resent the full range of genotypes identified. Only strains
showing growth of more than 1% of the inoculate were
scored as resistant.
PCR/ DNA sequencing
A 271 bp fragment of the rpoB gene containing the 81 bp
mutation hotspot (Cluster I) was amplified and
sequenced from the parent and all 131 mutants studied.
Crude DNA extracts were prepared for PCR by heating cell
suspensions to 95°C for 20 min in TE buffer containing
1% Triton X-100. PCR of rpoB cluster I was carried out on
all 132 isolates included in the study, in 20 µl volumes,
containing 2 µl 10× PCR buffer (Bioline Ltd., London,
UK); 0.5 unit Taq-DNA polymerase (Bioline); 0.5 µl 2
mM dNTP mixture (Bioline); 0.5 µl 20 µM primer mix
(containing rpoBP1, 5'ggtcggcatgtcgcggatgg and
rpoB1420R, 5'gtagtgcgacgggtgcacgtc) 15.5 µl water and 1
µl of DNA extract. Thermal cycling was performed in a
Thermocycler using the following programme 5 min at
95°C, 30 × (30 sec at 95°C, 30 sec at 65°C, 60 sec at
72°C), 5 min at 72°C. The presence of PCR products was
confirmed by agarose gel electrophoresis. These products
were diluted 1/100 in purified water and sequenced using
CEQ Quick Start sequencing kits and a CEQ 8000 instru-
ment (Beckman Coulter, High Wycombe, UK) according
to the manufacturer's instructions. The PCR products were
sequenced in both directions using the amplification
primers given above. All codon numbers are reported
using the E. coli numbering system.
An additional 365 bp region of the rpoB gene (containing
codon 176 [10]) from all 26 second round mutants and
the two parent strains was also amplified and sequenced
using primers rpob7F (cttctccgggtcgatgtcgttg) and rpob7R
(CGCGCTTGTCGACGTCAAACTC). PCR was carried out
in 25 µl volumes, containing 2.5 µl 10× HotGoldstar PCR
buffer (Eurogentec); 2 µl 25 mM MgCl2; 0.15 µl (5 units/
µl) HotGoldstar DNA polymerase (Eurogentec); 0.2 µl 25
mM dNTP mixture (Amersham Bioscience); 0.25 µl 10Page 2 of 6
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extract. Thermal cycling was performed in a Thermocycler
using the following programme: 10 min at 95°C, 35× (30
sec at 96°C, 30 sec at 60°C, 60 sec at 72°C). The presence
of PCR products was confirmed by agarose gel electro-
phoresis. These products were diluted 1/10 in purified
water and sequenced using the dideoxy chain termination
method with the Big Dye Terminator cycle sequencing Kit
(Applied Biosystems, CA, USA). PCR was carried out,
using quarter reactions with either the forward or reverse
primer. Sequence analysis was performed on a 310
Genetic Analyzer (Applied Biosystems).
Mutation frequency was measured by plating 1.5 ml of
two entirely independent exponentially growing bacterial
cultures in antibiotic free Middlebrook 7H9 broth onto a
series of Middlebrook 7H11 plates, one set containing 0.8
µg/ml and one set containing 8 µg/ml RFB. Decimal dilu-
tion series of each of these cultures were prepared and
plated onto non-selective Middlebrook 7H11 plates, the
CFU present on these plates was used to calculate the
inoculum size. The mutation frequency, calculated sepa-
rately for each drug concentration used, was the number
of resistant colonies / number of CFU inoculated.
Results
Mutations in the 81-bp locus of the MTB rpoB gene were
detected in cluster I (between codons 512 and 532) in all
105 first round resistant mutants that were sequenced
(Table 1); no mutations were detected in the parent strain
and two blinded wild type isolates included in this panel
as sequencing controls.
Two regions of the rpoB gene from 26 randomly selected
RFB second round mutants were sequenced (Table 2). Sin-
gle mutations in addition to the original S522L mutation
in the rpoB gene were identified in 24 of the 26 strains
(92%). Twelve strains had mutations between codons 505
and 531, and 12 strains had mutations between codons
144 and 148, the final two strains did not have any addi-
tional mutations in the regions sequenced. No (addi-
tional) mutations were detected in the two parent strains
(Mtb72 and R190) sequenced as controls.
The MICs of selected isolates representing the spectrum of
mutations obtained are shown in table 3. The single strain
identified as resistant to rifampicin (MIC 32 µg/ml) but
sensitive to rifabutin (strain R190, MIC<0.8 µg/ml, muta-
tion S522L) was subjected to a second round of selection
using RFB, in parallel with the parent strain (Mtb72). The
frequency of mutants produced after 28 days incubation
at 37°C by R190 (S522L) on two different RFB concentra-
tions was compared to the mutation frequency of the par-
ent strain. After selection with 0.8 µg/ml RFB the parent
strain generated RFB resistant mutants with a frequency of
1.25 × 10-7 colonies per CFU plated and the R190 (S522L)
mutant generated RFB resistant mutants with a frequency
of 1.93 × 10-6 per CFU plated. After selection with 8.0 µg/
ml RFB the parent strain generated RFB resistant mutants
with a frequency of 1.42 × 10-8 colonies per CFU plated
and the R190 mutant generated RFB resistant mutants
with a frequency of 1.7 × 10-7 per CFU plated. Thus, spon-
taneous RFB mutants were generated by R190 with 11.6
times the frequency of the parent strain with 8 µg/ml RFB
and 15.4 times the frequency of the parent strain with 0.8
µg/ml RFB.
Discussion
In this study a single M. tuberculosis isolate (R190), with a
S522L mutation, was detected that was resistant to RIF
(MIC 32 µg/ml) but remained sensitive to RFB (MIC <0.8
µg/ml) (Table 3). Specific mutations in codon 522 have
previously been shown to result in only low level RFB
resistance from clinical isolates of MTB [7,9]. The distribu-
tion of second round RFB mutations from R190 was strik-
ingly different from that obtained from the parent strain
(Table 2) and the frequency of resistant mutants increased
> 10 fold when measured on two separate occasions.
Additional second round mutations in the rpoB gene were
identified in 24 of 26 (92%) of the R190 second round
Table 1: Distribution of rpoB spontaneous mutations identified after in vitro exposure to rifampicin (8 µg/ml) or rifabutin (0.8 µg/ml).























1 0 5 27 6 0 6 1 1*
(Mtb72) (2) (0) (11) (60) (13) (0) (13) (2) (2) 47
Rifampicin 8 
µg/ml
0 1 6 26 4 1 20 0 0
(Mtb72) (0) (2) (11) (45) (7) (2) (35) (0) (0) 58
* = 525 ACC>ACG + 526 CAC>CCC + 527 AAG>CAGPage 3 of 6
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round of selection with rifabutin.
Strain Conc. of RFB used for selection µg/ml Additional mutations identified* codons 
505–531 (Cluster I 507–533)
Additional mutations identified* codons 
144–148
1 0.8 F505L TTC>TTA None
2 0.8 F505L TTC>TTG None
3 0.8 S512G AGC>GGC None
4 8 S512G AGC>GGC None
5 8 S512G AGC>GGC None
6 8 S512G AGC>GGC None
7 0.8 H526Y CAC>TAC None
8 8 H526Y CAC>TAC None
9 0.8 S531L TCG>TTG None
10 0.8 S531L TCG>TTG None
11 0.8 S531L TCG>TTG None
12 0.8 S531L TCG>TTG None
13 8 None V144M GTG>ATG
14 8 None V144M GTG>ATG
15 8 None V144G GTG>GGG
16 0.8 None V146F GTC>TTC
17 0.8 None V146F GTC>TTC
18 0.8 None V146F GTC>TTC
19 8 None V146F GTC>TTC
20 8 None V146F GTC>TTC
21 8 None V146F GTC>TTC
22 8 None Q148H CAG>CAC
23 0.8 None Q148H CAG>CAC
24 0.8 None Q148H CAG>CAC
25 0.8 None None
26 0.8 None None
*All isolates retained the original S522L TCG>TTG mutation from their R190 parent and had at most a single additional mutation identified. 
Codons are numbered according to the E. coli numbering system.
Table 3: Rifampicin and rifabutin MICs of selected first generation in vitro mutants.
rpoB Mutation Number of Isolates RIF MIC µg/ml Number of Isolates RFB MIC µg/ml
Wild 2 <4 2 <0.8
Q513L 1 256 1 >128
S522L 1 32 1 <0.8
H526Y 3 256 1 >128
1 128 2 128
1 64
H526D 3 256 1 >128
1 128 3 128
H526R 1 512 5 128
3 256
1 128
H526P 1 256 1 >128
S531L 4 256 1 >128
2 128
1 64
S531W 1 256 1 128Page 4 of 6
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were similar to those seen in the first round selection
(either in codon 526 or 531). A single mutant with a
change in codon 512 at the beginning of cluster I was also
identified. Mutations in codon 512 have only been
reported previously in association with additional muta-
tions [10] as in this study (S512G + S522L). The remain-
ing mutations were outside cluster 1, codons 144, 146,
148, and just before cluster I in codon 505 (Table 2).
This dramatic change in mutations identified indicates
either, the range of viable SNPs resulting in high-level RFB
resistance was significantly altered by the presence of the
S522L mutation, or the range of spontaneous mutations
occurring in this strain changed. Thus, it is possible, for
example, that the mutations in codon 505 occurred in
both cases but alone would not have resulted in resistance
or in the absence of the S522L mutation may be lethal.
Interestingly, these results could also be explained by a
change in both the frequency and spectrum of spontane-
ous mutations after the first round of selection, ie. the rate
of spontaneous mutations in codons 505, 512, 144, 146,
and 148, has increased after the first round of selection. As
9 different codon changes were identified among the 26
isolates tested (Table 2), from two independent experi-
ments (drug concentrations), a single spontaneous
mutant in an early generation of this culture (a "Jackpot"
mutation) [11] cannot explain this result.
The distribution of in vitro first round spontaneous muta-
tions in M. tuberculosis has previously been reported [5]
and 7 of the 9 codon changes identified were also seen in
this study. The most striking difference between this data
and the first round selection data presented here is the
higher frequency of the C>T H526Y mutation in our study
with both RIF and RFB. Some variation between random
selections of mutants would be expected and methodo-
logical differences, notably the use of a different bacterial
strain [5,12], probably contributed to this effect.
Mutations in codons 526 and 531 predominate in most of
the published studies but there is also some indication
that certain strains may be prone to develop specific muta-
tions [4,12] and marked differences in the distribution of
mutations have been observed in different geographical
locations [4,13]. Our data from the first round selection
(Table 1) suggest that for the strain and conditions we
used RFB may be more likely to select for C>T H526Y
mutations than rifampicin.
All first round mutations identified in this study have
been reported previously from clinical isolates [4,5,8-
10,14] except the one triple mutant identified (table 1).
The second round mutations seen in codons 505, 512,
144, and 148 present in addition to the S522L mutation
(Table 2), have to our knowledge not been reported pre-
viously from in vitro or clinical isolates. Although, it
should be noted that these mutations lie outside the 81 bp
hotspot region in a region of the rpoB gene that has been
subjected to much less extensive investigation.
The possibility of an MTB strain with altered or raised
mutation rate is important. Selection of a mutator pheno-
type is recognised as a consequence of antibiotic challenge
in many bacterial species [11,15]. The selection of strains
with increased mutation rates will result in a greater
chance of acquiring resistance to other drugs but may also
impact on the pathogenicity of the strain. It has been
reported that many MDR-MTB strains have, at least ini-
tially, reduced pathogenicity [16] and mutations in three
putative mutator genes as well as evidence for a reversion
back to a more pathogenic non-mutator state after the
acquisition of drug resistance has been reported in W-Bei-
jing strains [3]. However, some rpoB mutations are associ-
ated with only a modest decrease in in vitro fitness [17].
Interestingly, induction of the proposed MTB error prone
DNA repair enzyme was associated with survival of the
bacteria in vivo [1], so the effect of a mutator phenotype
on pathogenicity is difficult to predict [18].
In conclusion, the presence of a different spectrum of sec-
ondary rifabutin mutations implies that either, the muta-
tion rate of individual mutations has changed, due to a
defect in DNA repair or replication, or that additional
spontaneous mutations are viable (and lead to resistance)
in the presence of the S522L mutation [2]. A further con-
sequence of this observation is that a proportion clinical
isolates with mutations in cluster 1 of the rpoB gene asso-
ciated with rifampicin resistance only may in fact be resist-
ant to rifabutin as a consequence of addition mutations in
other regions of this gene. We believe further study is war-
ranted, of this and similar strains which should include
generating mutants to other antimicrobials and measur-
ing mutation rates [19,20], allowing the contribution of
each of these possible explanations to be explored. The
details of how resistance mutations arise would be valua-
ble when formulating standard treatment regimens with
the aim of minimising the emergence of resistance in
treated populations [21].
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